Page 153 - Revol6

Tomas Sánchez-Araña, M.ª Luz Torralba, M.ª José Montoya, M.ª Carmen Gómez y Rafael Touriño
27. De Hert M, Kalnicka D, van Winkel R, Wampers M, Hanssens
L, Van Eyck D,Scheen A, Peuskens J. Treatment with rosuvasta-
tin for severe dyslipidemia in patients with schizophrenia and
schizoaffective disorder.J Clin Psychiatry. 2006
Dec;67(12):1889-96.
28. De Hert M, Hautekeete M, De Wilde D, Peuskens J. High pre-
valence of Helicobacter pylori in institutionalized schizophrenic
patients. Schizophr Res 1997; 26: 243-44.
29. De León J. Smoking and vulnerability for schizophrenia.
Schizophr Bull. 1996; 22 (3): 405-9.
30. De León J, Díaz FJ. A meta-analysis of worldwide studies
demonstrates an association between schizophrenia and tobacco
smoking behaviors. Schizophr Res. 2005; 76 (2-3): 135-57.
31. De León J, Verghese C, Tracy JI, Josiassen RC, Simpson GM.
Polydipsia and water intoxication in psychiatric patients: A
review of the epidemiological literature. Biol Psychiatry 1994;
35: 408-19.
32. De León J, Becona E, Gurpegui M, González-Pinto A, Díaz FJ.
The association between high nicotine dependence and severe
mental illness may be consistent across countries. J Clin
Psychiatry. 2002; 63 (9): 812-6.
33. D’Ercole A, Skodol AE, Struening E, Curtis J, Millman J.
Diagnosis of physical illness in psychiatric patients using axis III
and a standardized medical history. Hosp Community Psychiatry.
1991; 42 (4): 395-400.
34. Dinwiddie SH, Shicker L, Newman T. Prevalence of hepatitis C
among psychiatric patients in the public sector. Am J Psychiatry.
2003; 160 (1):172-4.
35. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates
of diabetes in national schizophrenia samples. Schizophr Bull
2000; 26: 903-12.
36. Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The
association of medical comorbidity in schizophrenia with poor
physical and mental health. J Nerv Ment Dis 1999; 187; (8):
496-502.
37. Druss BG, Rosenheck RA, Desai MM, Perlin JB. Quality of pre-
ventive medical care for patients with mental disorders. Med
Care. 2002; 40 (2): 129-36.
38. Dworkin RH. Pain insesitivity in schizophrenia: A neglected
phenomenon and some implications . Schizophr Bull 1994; 20
(2): 235-48.
39. Eaton WW, Hayward C, Ram R. Schizophrenia and rheumatoid
arthritis: A review. Schizophr Res 1992; 6: 181-92.
40. Eaton W, Mortensen PB, Agerbo E, Byrne M, Mors O, Ewald H.
Coeliac disease and schizophrenia: population based case control
study with linkage of Danish national registers. BMJ. 2004; 328
(7437): 438-9.
41. Enger C, Weatherby, MS, Reynolds RF, et al. Serious cardiovas-
cular events and mortality among patients with schizophrenia.
The journal of nervous and mental disease, 2004, 192 :19-27.
42. Expert Group. ‘Schizophrenia and Diabetes 2003’ Expert
Consensus Meeting, Dublin, 3-4 October 2003: consensus sum-
mary. Br J Psychiatry Suppl. 2004; 47: 112-4.
43. Ferrer E, Varela R, Lamas S. Polidipsia e Intoxicación Hídrica en
la Esquizofrenia Crónica. Revisión de la Bibliografía. 2000; 4 (1).
Consultado el 23 de Abril de 2004 en: www. psiquiatría.com
artículos/psicosis/esquizofrenia.
44. Ford ES. The metabolic syndrome and mortality from cardiovas-
cular disease and all-causes: findings from the National Health
and Nutrition Examination Survey II Mortality Study.
Atherosclerosis. 2004; 173 (2): 309-14.
45. Glassman AH, Schizophrenia, antipsychotics drugs and cardio-
vascular disease. J Clin Psychiatry 2005; 66 (Suppl 6): 5-10.
46. Glazer WM. Extrapyramidal side effects, tardive dyskinesia and
the concept of atypicality. J Clin Psychiatry 2000; 61(Suppl
3):16-21
47. oldman LS. Medical illness in patients with schizophrenia. J Clin
Psychiatry 1999; 60 (Suppl 21): 10-5.
48. Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O et
al. Medical Morbidity and Mortality in Schizophrenia:
Guidelines for Psychiatrists. J Clin Psychiatry 2005a ; 66: 183-
94.
49. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA,
Daumit GL, Lamberti S, D’Agostino RB, Stroup TS, Davis S,
160 Evaluación en Rehabilitación Psicosocial
Lieberman JA. A comparison of ten-year cardiac risk estimates in
schizophrenia patients from the CATIE study and matched con-
trols.Schizophr Res. 2005b; 80 (1):45-53.
50. Goldacre MJ, Kurina LM, Wotton CJ, Yeates D, Seagroat V.
Schizophrenia and cancer: an epidemiological study.Br J
Psychiatry. 2005; 187: 334-8.
51. Gorwood P, Pouchot J, Vinceneux P, Puechal X, Flipo RM, De
Bandt M, Ades J; Club Rhumatisme et Inflammation.
Rheumatoid arthritis and schizophrenia: a negative association at
a dimensional level. Schizophr Res. 2004; 66(1):21-9.
52. Graupner C, Rodriguez L, Garcia A. Síndrome metabólico e
hipertension arterial. Monocardio N.º 3. 2003; Vol 5: 167– 76.
53. Green AI. Schizophrenia and comorbid substance use disorder:
effects of antipsychotics. J Clin Psychiatry. 2005; 66 (Suppl 6):
21-6.
54. Green AI, Canuso CM, Brenner MJ, Wojcik JD. Detection and
management of comorbidity in patients with schizophrenia.
Psychiatr Clin North Am. 2003; 26 (1): 115-39.
55. Grinshpoon A, Barchana M, Ponizovsky A, et al. Cancer in
Schizophrenia: is the risk higher or lower? Schizophrenia
Research. 2005; 73: 333-41.
56. Gupta S, Masand PS, Kaplan D, et al. The relationship between
schizophrenia and irritable bowel syndrome (IBS). Schizophr Res
1997; 23: 265-68.
57. Haddad P. Weight change with atypical antipsychotics in the
treatment of schizophrenia. J Psychopharmacol. 2005; 19 (Suppl
6): 16-27.
58. Halbreich U, Shen J, Panaro V. Are chronic psychiatric patients
at increased risk for developing breast cancer? Am J Psychiatry
1996; 153: 559-56.
59. Hansen V, Jacobsen BK, Arnesen E. Cause-specific mortality in
psychiatric patients after deinstitutionalisation. Br J Psychiatry.
2001; 179: 438-43.
60. Harris EC, Barraclough B. Excess of mortality of mental disor-
ders. Br J Psychiatry 1998; 177:11-53.
61. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic
medications. J Clin Psychiatry. 2001; 62 (Suppl 27):15-26.
62. Henderson DC, Ettinger ER. Schizophrenia and diabetes. Int
Rev Neurobiol. 2002; 51: 481-501.
63. Henderson DC. Schizophrenia and comorbid metabolic disor-
ders. J Clin Psychiatry. 2005;66 (Suppl 6): 11-20.
64. Hennekens CH, Hennekens AR, Hollar D, Casey DE.
Schizophrenia and increased risks of cardiovascular disease.Am
Heart J. 2005; 150 (6):1115-21.
65. HeathertonTF, Kozlowski LT, Frecker RC, Fagerström KO. The
Fagerström Test for Nicotine Dependence: a revision of the
Fagerström Tolerance Questionnaire. Br J Addict. 1991; 86:
1119-27.
66. Heila H, Haukka J, Suvisaari J, Lonnqvist J. Mortality among
patients with schizophrenia and reduced psychiatric hospital
care. Psychol Med. 2005; 35 (5): 725-32.
67. Homel P, Casey D, Allison DB. Changes in body mass index for
individuals with and without schizophrenia, 1987-1996.
Schizophr Res. 2002; 55 (3): 277-84.
68. Hummer M, Malik P, Gasser RW, Hofer A, Kemmler G,
Moncayo Naveda RC, Rettenbacher MA, Fleischhacker WW.
Osteoporosis in patients with schizophrenia. Am J Psychiatry.
2005; 162 (1): 162-7.
69. Hyde TM , Lewis SW. The secondary schizophrenias. En Hirsch
SR, Weinberger DR, (eds). Schizophrenia. Oxford: Blackwell;
2003. Pág:187-202.
70. Jests DV. Tardive dyskinesia in older patients. J Clin Psychiatry
2000; 61 (Suppl 4): 27–32.
71. Jeste D, Gladsjo J, Lindamer L, Lacro J. Medical comorbidity in
schizophrenia. Schizophr Bull 1996; 22: 413-30.
72. Jones DR, Macias C, Barreira PJ, Fisher WH, Hargreaves WA,
Harding CM. Prevalence, severity, and co-occurrence of chronic
physical health problems of persons with serious mental illness.
Psychiatr Serv. 2004; 55 (11):1250-7.
73. Joukamaa M, Heliovaara M, Knekt P, et al. Schizophrenia, neuro-
leptic medication and mortality. Br J Psychiatry. 2006; 188: 122-7.
74. Karasu TB, Waltzman SA, Lindenmayer JP, Buckley PJ. The
medical care of patients with psychiatric illness. Hosp
Community Psychiatry. 1980; 31 (7): 463-72.